In vitro and in vivo model systems for studying enteropathogenic Escherichia coli infections

Cold Spring Harbor Perspectives in Medicine

Volumn 3, Issue 3, 2013, Pages

  Law, Robyn J ^a,b   Gur Arie, Lihi ^c   Rosenshine, Ilan ^c   Brett Finlay, B ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL; BIOLOGICAL MODEL; CELL CULTURE; CELL LINE; DISEASE MODEL; ENTEROPATHOGENIC ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; GASTROENTERITIS; HUMAN; MICROBIOLOGY; PATHOGENICITY; REVIEW;

ANIMALS; CELL LINE; CELLS, CULTURED; DISEASE MODELS, ANIMAL; ENTEROPATHOGENIC ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; GASTROENTERITIS; HUMANS; MODELS, BIOLOGICAL;

EID: 84882263652     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a009977     Document Type: Article

References (126)

1. Abe A., Kenny B, Stein M, Finlay BB. 1997. Characterization of two virulence proteins secreted by rabbit enteropathogenic Escherichia coli, EspA and EspB, whose maximal expression is sensitive to host body temperature. Infect Immun 65: 3547-3555.
2. Abe A., Heczko U, Hegele RG, Finlay BB. 1998. Two enteropathogenic Escherichia coli type III secreted proteins, EspA and EspB, are virulence factors. J Exp Med 188: 1907-1916.
3. Anyanful A., Dolan-Livengood JM, Lewis T, Sheth S, Dezalia MN, Sherman MA, Kalman LV, Benian GM, Kalman D. 2005. Paralysis and killing of Caenorhabditis elegans by enteropathogenic Escherichia coli requires the bacterial tryptophanase gene. Mol Microbiol 57: 988-1007.
4. Anyanful A., Easley KA, Benian GM, Kalman D. 2009. Conditioning protects C. elegans from lethal effects of enteropathogenic E. coli by activating genes that regulate lifespan and innate immunity. Cell Host Microbe 5: 450-462.
5. Arumugam M., Raes J, Pelletier E, Le Paslier D, Yamada T, Mende D.R., Fernandes GR, Tap J, Bruls T, Batto JM, et al. 2011. Enterotypes of the human gut microbiome. Nature 473: 174-180.
6. Bai L., Schüller S, Whale A, Mousnier A, MarchesO, Wang L, Ooka T., Heuschkel R, Torrente F, Kaper JB, et al. 2008. Enteropathogenic Escherichia coli O125:H6 triggers attaching and effacing lesions on human intestinal biopsy specimens independently of Nck and TccP/TccP2. Infect Immun 76: 361-368.
7. Barthold S.W., Coleman GL, Jacoby RO, Livestone EM, Jonas AM. 1978. Transmissible murine colonic hyperplasia. Vet Pathol 15: 223-236.
8. Baruch K., Gur-Arie L, Nadler C, Koby S, Yerushalmi G, Ben-Neriah Y., YogevO, Shaulian E, Guttman C, Zarivach R, et al. 2011. Metalloprotease type III effectors that specifically cleave JNK and NF-κB. EMBO J 30: 221-231.
9. Berger C.N., Sodha SV, Shaw RK, Griffin PM, PinkD, Hand P, Frankel G. 2010. Fresh fruit and vegetables as vehicles for the transmission of human pathogens. EnvironMicrobiol 12: 2385-2397.
10. Bhatt S., Anyanful A, Kalman D. 2011. CsrA and TnaB coregulate tryptophanase activity to promote exotoxininduced killing of Caenorhabditis elegans by enteropathogenic Escherichia coli. J Bacteriol 193: 4516-4522.
11. Bieber D., Ramer SW, Wu CY, Murray WJ, Tobe T, Fernandez R, Schoolnik GK. 1998. Type IV pili, transient bacterial aggregates, and virulence of enteropathogenic Escherichia coli. Science (New York, NY) 280: 2114-2118.
12. Borenshtein D., McBee ME, Schauer DB. 2008. Utility of the Citrobacter rodentium infection model in laboratory mice. Curr Opin Gastroenterol 24: 32-37.
13. Brenner S. 1974. The genetics of Caenorhabditis elegans. Genetics 77: 71-94.
14. Campellone KG. 2010. Cytoskeleton-modulating effectors of enteropathogenic and enterohaemorrhagic Escherichia coli: Tir, EspFU and actin pedestal assembly. FEBS J 277: 2390-2402.
15. Coburn B., Sekirov I, Finlay BB. 2007. Type III secretion systems and disease. Clin Microbiol Rev 20: 535-549.
16. Cornelis GR. 2006. The type III secretion injectisome. Nat Rev Microbiol 4: 811-825.
17. Croxen M.A., Finlay BB. 2010. Molecular mechanisms of Escherichia coli pathogenicity. Nat Rev Microbiol 8: 26-38.
18. Dean P., Kenny B. 2004. Intestinal barrier dysfunction by enteropathogenic Escherichia coli is mediated by two effector molecules and a bacterial surface protein. Mol Microbiol 54: 665-675.
19. Dean P., Kenny B. 2009. The effector repertoire of enteropathogenic E. coli: Ganging up on the host cell. Curr Opin Microbiol 12: 101-109.
20. Dean P., Maresca M, Kenny B. 2005. EPEC's weapons of mass subversion. Curr Opin Microbiol 8: 28-34.
21. Dean-Nystrom EA, Gansheroff LJ, Mills M, Moon HW, O'Brien AD. 2002. Vaccination of pregnant dams with intimin(O157) protects suckling piglets from Escherichia coli O157:H7 infection. Infect Immun 70: 2414-2418.
22. DengW, Li Y, Vallance BA, Finlay BB. 2001. Locus of enterocyte effacement from Citrobacter rodentium: Sequence analysis and evidence for horizontal transfer among attaching and effacing pathogens. Infect Immun 69: 6323-6335.
23. Deng W., Vallance BA, Li Y, Puente JL, Finlay BB. 2003. Citrobacter rodentium translocated intimin receptor (Tir) is an essential virulence factor needed for actin condensation, intestinal colonization and colonic hyperplasia in mice. Mol Microbiol 48: 95-115.
24. Deng W., Puente JL, Gruenheid S, Li Y, Vallance BA, Vázquez A, Barba J, Ibarra JA, O'Donnell P, Metalnikov P, et al. 2004. Dissecting virulence: Systematic and functional analyses of a pathogenicity island. Proc Natl Acad Sci 101: 3597-3602.
25. DengW, de Hoog CL, Yu HB, Li Y, Croxen MA, ThomasNA, Puente J.L., Foster LJ, Finlay BB. 2010. A comprehensive proteomic analysis of the type III secretome of Citrobacter rodentium. J Biol Chem 285: 6790-6800.
26. Deng W., Yu HB, de Hoog CL, Stoynov N, Li Y, Foster LJ, Finlay BB. 2012. Quantitative proteomic analysis of type III secretome of Enteropathogenic E. coli reveals an expanded effector repertoire for attaching/effacing bacterial pathogens. Mol Cell Proteomics 11: 692-709.
27. Dennis A., Kudo T, Kruidenier L, Girard F, Crepin VF, MacDonald T.T., Frankel G, Wiles S. 2008. The p50 subunit of NF-κB is critical for in vivo clearance of the noninvasive enteric pathogen Citrobacter rodentium. Infect Immun76: 4978-4988.
28. Dong N., Liu L, Shao F. 2010. A bacterial effector targets host DH-PH domain RhoGEFs and antagonizes macrophage phagocytosis. EMBO J 29: 1363-1376.
29. Donnenberg M.S., Tacket CO, James SP, Losonsky G, Nataro JP, Wasserman SS, Kaper JB, Levine MM. 1993. Role of the eaeA gene in experimental enteropathogenic Escherichia coli infection. J Clin Invest 92: 1412-1417.
30. Eaton K.A., Friedman DI, Francis GJ, Tyler JS, Young VB, Haeger J., Abu-Ali G, Whittam TS. 2008. Pathogenesis of renal disease due to enterohemorrhagic Escherichia coli in germ-free mice. Infect Immun 76: 3054-3063.
31. Eaton K.A., Honkala A, Auchtung TA, Britton RA. 2011. Probiotic Lactobacillus reuteri ameliorates disease due to enterohemorrhagic Escherichia coli in germfree mice. Infect Immun 79: 185-191.
32. FoubisterV, Rosenshine I, Donnenberg MS, Finlay BB. 1994. The eaeB gene of enteropathogenic Escherichia coli is necessary for signal transduction in epithelial cells. Infect Immun 62: 3038-3040.
33. Frankel G., Phillips AD. 2008. Attaching effacing Escherichia coli and paradigms of Tir-triggered actin polymerization: Getting off the pedestal. Cell Microbiol 10: 549-556.
34. Frankel G., Phillips AD, Novakova M, Field H, Candy DC, Schauer D.B., Douce G, Dougan G. 1996. Intimin from enteropathogenic Escherichia coli restores murine virulence to a Citrobacter rodentium eaeA mutant: Induction of an immunoglobulin A response to intimin and EspB. Infect Immun 64: 5315-5325.
35. Frankel G., Philips AD, Novakova M, Batchelor M, Hicks S, Dougan G. 1998a. Generation of Escherichia coli intimin derivatives with differing biological activities using sitedirected mutagenesis of the intimin C-terminus domain. Mol Microbiol 29: 559-570.
36. Frankel G., Phillips AD, Rosenshine I, Dougan G, Kaper JB, Knutton S. 1998b. Enteropathogenic and enterohaemorrhagic Escherichia coli: More subversive elements. Mol Microbiol 30: 911-921.
37. Ghaem-Maghami M, Simmons CP, Daniell S, Pizza M, Lewis D., Frankel G, Dougan G. 2001. Intimin-specific immune responses prevent bacterial colonization by the attaching-effacing pathogen Citrobacter rodentium. Infect Immun 69: 5597-5605.
38. Gibson D.L., Ma C, Bergstrom KSB, Huang JT, Man C, Vallance BA. 2008. MyD88 signalling plays a critical role in host defence by controlling pathogen burden and promoting epithelial cell homeostasis during Citrobacter rodentium-induced colitis. Cell Microbiol 10: 618-631.
39. Girard F., Batisson I, Frankel GM, Harel J, Fairbrother JM. 2005. Interaction of enteropathogenic and Shiga toxinproducing Escherichia coli and porcine intestinal mucosa: Role of intimin and Tir in adherence. Infect Immun 73: 6005-6016.
40. Golan L., Gonen E, Yagel S, Rosenshine I, Shpigel NY. 2011. Enterohemorrhagic Escherichia coli induce attaching and effacing lesions and hemorrhagic colitis in human and bovine intestinal xenograft models. Dis Model Mech 4: 86-94.
41. Goosney D.L., Celli J, Kenny B, Finlay BB. 1999. Enteropathogenic Escherichia coli inhibits phagocytosis. Infect Immun 67: 490-495.
42. Goosney D.L., Gruenheid S, Finlay BB. 2000. Gut feelings: Enteropathogenic E. coli (EPEC) interactions with the host. Ann Rev Cell Dev Biol 16: 173-189.
43. Gruenheid S., DeVinney R, Bladt F, Goosney D, Gelkop S, Gish G.D., Pawson T, Finlay BB. 2001. Enteropathogenic E. coli Tir binds Nck to initiate actin pedestal formation in host cells. Nat Cell Biol 3: 856-859.
44. Gruenheid S., Sekirov I, Thomas NA, DengW, O'Donnell P, Goode D., Li Y, Frey EA, Brown NF, Metalnikov P, et al. 2004. Identification and characterization of NleA, a non-LEE-encoded type III translocated virulence factor of enterohaemorrhagic Escherichia coli O157:H7. Mol Microbiol 51: 1233-1249.
45. Hayashi T., Makino K, Ohnishi M, Kurokawa K, Ishii K, Yokoyama K, Han CG, Ohtsubo E, Nakayama K, Murata T., et al. 2001. Complete genome sequence of enterohemorrhagic Escherichia coli O157:H7 and genomic comparison with a laboratory strain K-12. DNA Res 8: 11-22.
46. Hilbi H., Weber SS, Ragaz C, Nyfeler Y, Urwyler S. 2007. Environmental predators as models for bacterial pathogenesis. Environ Microbiol 9: 563-575.
47. Iguchi A., Thomson NR, Ogura Y, Saunders D, Ooka T, Henderson I.R., Harris D, Asadulghani M, Kurokawa K, Dean P., et al. 2009. Complete genome sequence and comparative genome analysis of enteropathogenic Escherichia coli O127:H6 strain E2348/69. J Bacteriol 191: 347-354.
48. Inman L.R., Cantey JR. 1983. Specific adherence of Escherichia coli (strain RDEC-1) to membranous (M) cells of the Peyer's patch in Escherichia coli diarrhea in the rabbit. J Clin Invest 71: 1-8.
49. Ivanov I.I., Atarashi K, Manel N, Brodie EL, Shima T, Karaoz U., Wei D, Goldfarb KC, Santee CA, Lynch SV, et al. 2009. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 139: 485-498.
50. Jenkins C., Lawson AJ, Cheasty T, Willshaw GA, Wright P, Dougan G., Frankel G, Smith HR. 2003. Subtyping intimin genes from enteropathogenic Escherichia coli associated with outbreaks and sporadic cases in the United Kingdom and Eire. Mol Cell Probe 17: 149-156.
51. Kalman D., Weiner OD, Goosney DL, Sedat JW, Finlay BB, Abo A., Bishop JM. 1999. Enteropathogenic E. coli acts through WASP and Arp2/3 complex to form actin pedestals. Nat Cell Biol 1: 389-391.
52. Kaper J.B., Nataro JP, Mobley HL. 2004. Pathogenic Escherichia coli. Nat Rev Microbiol 2: 123-140.
53. Kelly M., Hart E, Mundy R, Marchès O, Wiles S, Badea L, Luck S., Tauschek M, Frankel G, Robins-Browne RM, et al. 2006. Essential role of the type III secretion system effector NleB in colonization of mice by Citrobacter rodentium. Infect Immun 74: 2328-2337.
54. Kenny B. 2002. Mechanism of action of EPEC type III effector molecules. Int J Med Microbiol 291: 469-477.
55. Kenny B., DeVinney R, Stein M, Reinscheid DJ, Frey EA, Finlay BB. 1997. Enteropathogenic E. coli (EPEC) transfers its receptor for intimate adherence into mammalian cells. Cell 91: 511-520.
56. Klapproth J.M., Sasaki M, Sherman M, Babbin B, Donnenberg MS, Fernandes PJ, Scaletsky ICA, Kalman D, Nusrat A., Williams IR. 2005. Citrobacter rodentium lifA/efa1 is essential for colonic colonization and crypt cell hyperplasia in vivo. Infect Immun 73: 1441-1451.
57. Knutton S., Lloyd DR, McNeish AS. 1987. Adhesion of enteropathogenic Escherichia coli to human intestinal enterocytes and cultured human intestinal mucosa. Infect Immun 55: 69-77.
58. Knutton S., Baldwin T, Williams PH, McNeish AS. 1989. Actin accumulation at sites of bacterial adhesion to tissue culture cells: Basis of a new diagnostic test for enteropathogenic and enterohemorrhagic Escherichia coli. Infect Immun 57: 1290-1298.
59. Kum W.W.S., Lo BC, Deng W, Ziltener HJ, Finlay BB. 2010. Impaired innate immune response and enhanced pathology during Citrobacter rodentium infection in mice lacking functional P-selectin. Cell Microbiol 12: 1250-1271.
60. Kurz C.L., Ewbank JJ. 2000. Caenorhabditis elegans for the study of host-pathogen interactions. Trends Microbiol 8: 142-144.
61. Kurz C.L., Ewbank JJ. 2003. Caenorhabditis elegans: An emerging genetic model for the study of innate immunity. Nat Rev Genet 4: 380-390.
62. Larsen P.L., Albert PS, Riddle DL. 1995. Genes that regulate both development and longevity in Caenorhabditis elegans. Genetics 139: 1567-1583.
63. Lebeis S.L., Bommarius B, Parkos CA, Sherman MA, Kalman D. 2007. TLR signaling mediated by MyD88 is required for a protective innate immune response by neutrophils to Citrobacter rodentium. J Immunol 179: 566-577.
64. Luperchio S.A., Schauer DB. 2001. Molecular pathogenesis of Citrobacter rodentium and transmissible murine colonic hyperplasia. Microbes Infect 3: 333-340.
65. MacDonald TT, Frankel G, Dougan G, Goncalves NS, Simmons C. 2003. Host defences to Citrobacter rodentium. Int J Med Microbiol 293: 87-93.
66. Marchès O, Nougayrède JP, Boullier S, Mainil J, Charlier G, Raymond I., Pohl P, Boury M, De Rycke J, Milon A, et al. 2000. Role of Tir and intimin in the virulence of rabbit enteropathogenic Escherichia coli serotype O103:H2. Infect Immun 68: 2171-2182.
67. Marchès O, Covarelli V, Dahan S, Cougoule C, Bhatta P, Frankel G., Caron E. 2008. EspJ of enteropathogenic and enterohaemorrhagic Escherichia coli inhibits opsono-phagocytosis. Cell Microbiol 10: 1104-1115.
68. Martinez-Argudo I, Sands C, Jepson MA. 2007. Translocation of enteropathogenic Escherichia coli across an in vitro Mcell model is regulated by its type III secretion system. Cell Microbiol 9: 1538-1546.
69. McDaniel TK, Jarvis KG, Donnenberg MS, Kaper JB. 1995. A genetic locus of enterocyte effacement conserved among diverse enterobacterial pathogens. Proc Natl Acad Sci 92: 1664-1668.
70. McNamara BP, Koutsouris A, O'Connell CB, Nougayréde JP, Donnenberg M.S., Hecht G. 2001. Translocated EspF protein from enteropathogenic Escherichia coli disrupts host intestinal barrier function. J Clin Invest 107: 621-629.
71. McNeilly TN, Mitchell MC, Rosser T, McAteer S, Low JC, Smith D.G.E., Huntley JF, Mahajan A, Gally DL. 2010. Immunization of cattle with a combination of purified intimin-531, EspA and Tir significantly reduces shedding of Escherichia coli O157:H7 following oral challenge. Vaccine 28: 1422-1428.
72. Mellies J.L., Barron AMS, Haack KR, Korson AS, Oldridge DA. 2006. The global regulator Ler is necessary for enteropathogenic Escherichia coli colonization of Caenorhabditis elegans. Infect Immun 74: 64-72.
73. Mills E., Baruch K, Charpentier X, Kobi S, Rosenshine I. 2008. Real-time analysis of effector translocation by the type III secretion system of enteropathogenic Escherichia coli. Cell Host Microbe 3: 104-113.
74. Misyurina O., Asper DJ, Deng W, Finlay BB, Rogan D, Potter AA. 2010. The role of Tir, EspA, and NleB in the colonization of cattle by Shiga toxin producing Escherichia coli O26:H11. Can J Microbiol 56: 739-747.
75. Miyamoto Y., Iimura M, Kaper JB, Torres AG, Kagnoff MF. 2006. Role of Shiga toxin versus H7 flagellin in enterohaemorrhagic Escherichia coli signalling of human colon epithelium in vivo. Cell Microbiol 8: 869-879.
76. Mohawk K.L., O'Brien AD. 2011. Mouse models of Escherichia coli O157:H7 infection and shiga toxin injection. 2011. J Biomed Biotechnol 2011: 258185.
77. Mundy R., Petrovska L, Smollett K, Simpson N, Wilson RK, Yu J., Tu X, Rosenshine I, Clare S, Dougan G, et al. 2004. Identification of a novel Citrobacter rodentium type III secreted protein, EspI, and roles of this and other secreted proteins in infection. Infect Immun 72: 2288-2302.
78. Mundy R., Girard F, FitzGerald AJ, Frankel G. 2006. Comparison of colonization dynamics and pathology of mice infected with enteropathogenic Escherichia coli, enterohaemorrhagic E. coli and Citrobacter rodentium. FEMS Microbiol Lett 265: 126-132.
79. Mundy R., Schüller S, Girard F, Fairbrother JM, Phillips AD, Frankel G. 2007. Functional studies of intimin in vivo and ex vivo: Implications for host specificity and tissue tropism. Microbiology 153: 959-967.
80. Mylonakis E., Aballay A. 2005. Worms and flies as genetically tractable animal models to study host-pathogen interactions. Infect Immun 73: 3833-3841.
81. Nadler C., Baruch K, Kobi S, Mills E, Haviv G, Farago M, Alkalay I., Bartfeld S, Meyer TF, Ben-Neriah Y, et al. 2010. The type III secretion effector NleE inhibits NF-κB activation. PLoS Pathog 6: e1000743.
82. Nataro J.P., Kaper JB. 1998. Diarrheagenic Escherichia coli. Clin Microbiol Rev 11: 142-201.
83. Newman J.V., Zabel BA, Jha SS, SchauerDB. 1999. Citrobacter rodentium espB is necessary for signal transduction and for infection of laboratory mice. Infect Immun 67: 6019-6025.
84. Nieto-Pelegrin E, Martinez-Quiles N. 2009. Distinct phosphorylation requirements regulate cortactin activation by TirEPEC and its binding toN-WASP. CellCommun Signal 7: 11.
85. Ogura Y., Ooka T, Iguchi A, Toh H, Asadulghani M, Oshima K., Kodama T, Abe H, Nakayama K, Kurokawa K, et al. 2009. Comparative genomics reveal the mechanism of the parallel evolution of O157 and non-O157 enterohemorrhagic Escherichia coli. Proc Natl Acad Sci 106: 17939-17944.
86. Ota N., Wong K, Valdez P, Zheng Y, Crellin NK, Diehl L, OuyangW. 2011. IL-22 bridges the lymphotoxin pathway with the maintenance of colonic lymphoid structures during infection with Citrobacter rodentium. Nat Immun 12: 941-948.
87. Panos G.Z., Betsi GI, Falagas ME. 2006. Systematic review: Are antibiotics detrimental or beneficial for the treatment of patients with Escherichia coli O157:H7 infection? Aliment Pharmacol Ther 24: 731-742.
88. Perna N.T., Plunkett G, Burland V, Mau B, Glasner JD, Rose D.J., MayhewGF, Evans PS, Gregor J, Kirkpatrick HA, et al. 2001. Genome sequence of enterohaemorrhagic Escherichia coli O157:H7. Nature 409: 529-533.
89. Petty N.K., Bulgin R, Crepin VF, Cerdeño-Tárraga AM, Schroeder G.N., Quail MA, Lennard N, Corton C, Barron A., Clark L, et al. 2010. The Citrobacter rodentium genome sequence reveals convergent evolution with human pathogenic Escherichia coli. J Bacteriol 192: 525-538.
90. Pflughoeft K.J., Versalovic J. 2011. Human microbiome in health and disease. Annu Rev Pathol 7: 99-122.
91. Potter A.A., Klashinsky S, Li Y, Frey E, Townsend H, Rogan D, Erickson G., Hinkley S, Klopfenstein T, Moxley RA, et al. 2004. Decreased shedding of Escherichia coli O157:H7 by cattle following vaccination with type III secreted proteins. Vaccine 22: 362-369.
92. Quitard S., Dean P, Maresca M, Kenny B. 2006. The enteropathogenic Escherichia coli EspF effector molecule inhibits PI-3 kinase-mediated uptake independently of mitochondrial targeting. Cell Microbiol 8: 972-981.
93. Raymond B., Crepin VF, Collins JW, Frankel G. 2011. The WxxxE effector EspT triggers expression of immune mediators in an Erk/JNK and NF-κB-dependent manner. Cell Microbiol 13: 1881-1893.
94. Rhee K.J., Cheng H, Harris A, Morin C, Kaper JB, Hecht G. 2011. Determination of spatial and temporal colonization of enteropathogenic E. coli and enterohemorrhagic E. coli in mice using bioluminescent in vivo imaging. Gut Microbes 2: 34-41.
95. Robins-Browne RM, Tokhi AM, Adams LM, Bennett-Wood V. 1994a. Host specificity of enteropathogenic Escherichia coli from rabbits: Lack of correlation between adherence in vitro and pathogenicity for laboratory animals. Infect Immun 62: 3329-3336.
96. Robins-Browne RM, Tokhi AM, Adams LM, Bennett-Wood V., Moisidis AV, Krejany EO, O'Gorman LE. 1994b. Adherence characteristics of attaching and effacing strains of Escherichia coli from rabbits. Infect Immun 62: 1584-1592.
97. Rosenshine I., Ruschkowski S, Stein M, Reinscheid DJ, Mills S.D., Finlay BB. 1996. A pathogenic bacterium triggers epithelial signals to form a functional bacterial receptor that mediates actin pseudopod formation. EMBO J 15: 2613-2624.
98. Roxas J.L., Koutsouris A, Bellmeyer A, Tesfay S, Royan S, Falzari K., Harris A, Cheng H, Rhee KJ, Hecht G. 2010. Enterohemorrhagic E. coli alters murine intestinal epithelial tight junction protein expression and barrier function in a Shiga toxin independent manner. Lab Invest 90: 1152-1168.
99. Royan S.V., Jones RM, Koutsouris A, Roxas JL, Falzari K, Weflen A.W., Kim A, Bellmeyer A, Turner JR, Neish AS, et al. 2010. Enteropathogenic E. coli non-LEE encoded effectors NleH1 and NleH2 attenuate NF-κB activation. Mol Microbiol 78: 1232-1245.
100. Savkovic S.D., Villanueva J, Turner JR, Matkowskyj KA, Hecht G. 2005. Mouse model of enteropathogenic Escherichia coli infection. Infect Immun 73: 1161-1170.
101. Scallan E., Hoekstra RM, Angulo FJ, Tauxe RV, Widdowson MA, Roy SL, Jones JL, Griffin PM. 2011. Foodborne illness acquired in the United States-Major pathogens. Emerg Infect Dis 17: 7-15.
102. Schauer D.B., Falkow S. 1993. The eae gene of Citrobacter freundii biotype 4280 is necessary for colonization in transmissible murine colonic hyperplasia. Infect Immun 61: 4654-4661.
103. Schulenburg H., Kurz CL, Ewbank JJ. 2004. Evolution of the innate immune system: The worm perspective. Immunol Rev 198: 36-58.
104. Schüller S, Chong Y, Lewin J, Kenny B, Frankel G, Phillips AD. 2007. Tir phosphorylation and Nck/N-WASP recruitment by enteropathogenic and enterohaemorrhagic Escherichia coli during ex vivo colonization of human intestinal mucosa is different to cell culture models. Cell Microbiol 9: 1352-1364.
105. Schüller S, Lucas M, Kaper JB, Girón JA, Phillips AD. 2009. The ex vivo response of human intestinal mucosa to enteropathogenic Escherichia coli infection. Cell Microbiol 11: 521-530.
106. Sears CL. 2000. Molecular physiology and pathophysiology of tight junctions V. assault of the tight junction by enteric pathogens. Am J Physiol Gastrointest Liver Physiol 279: G1129-G1134.
107. Sekirov I., Finlay BB. 2009. The role of the intestinal microbiota in enteric infection. J Physiol 587: 4159-4167.
108. Szabady R.L., Lokuta MA, Walters KB, Huttenlocher A, Welch RA. 2009. Modulation of neutrophil function by a secreted mucinase of Escherichia coli O157:H7. PLoS Pathog 5: e1000320.
109. Tacket C.O., Sztein MB, Losonsky G, Abe A, Finlay BB, Mc-Namara B.P., Fantry GT, James SP, Nataro JP, Levine MM, et al. 2000. Role of EspB in experimental human enteropathogenic Escherichia coli infection. Infect Immun 68: 3689-3695.
110. Takahashi M., Taguchi H, Yamaguchi H, Osaki T, Komatsu A, Kamiya S. 2004. The effect of probiotic treatment with Clostridium butyricum on enterohemorrhagic Escherichia coli O157:H7 infection in mice. FEMS Immunol Med Microbiol 41: 219-226.
111. Tan M.W., Mahajan-Miklos S, Ausubel FM. 1999. Killing of Caenorhabditis elegans by Pseudomonas aeruginosa used to model mammalian bacterial pathogenesis. Proc Natl Acad Sci 96: 715-720.
112. Tarr P.I., Gordon CA, Chandler WL. 2005. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 365: 1073-1086.
113. Tauschek M., Strugnell RA, Robins-Browne RM. 2002. Characterization and evidence of mobilization of the LEE pathogenicity island of rabbit-specific strains of enteropathogenic Escherichia coli. Mol Microbiol 44: 1533-1550.
114. Thanabalasuriar A., Koutsouris A, Weflen A, Mimee M, Hecht G., Gruenheid S. 2010. The bacterial virulence factor NleA is required for the disruption of intestinal tight junctions by enteropathogenic Escherichia coli. Cell Microbiol 12: 31-41.
115. Tobe T., Beatson SA, Taniguchi H, Abe H, Bailey CM, Fivian A., Younis R, Matthews S, Marches O, Frankel G, et al. 2006. An extensive repertoire of type III secretion effectors in Escherichia coli O157 and the role of lambdoid phages in their dissemination. Proc Natil Acad Sci 103: 14941-14946.
116. Umanski T., Rosenshine I, Friedberg D. 2002. Thermoregulated expression of virulence genes in enteropathogenic Escherichia coli. Microbiology 148: 2735-2744.
117. Vallance B.A., Deng W, Knodler LA, Finlay BB. 2002. Mice lacking Tand B lymphocytes develop transient colitis and crypt hyperplasia yet suffer impaired bacterial clearance during Citrobacter rodentium infection. Infect Immun 70: 2070-2081.
118. Vallance B.A., Khan MA, Deng W, Gruenheid S, Finlay BB. 2004. Modeling enteropathogenic and enterohemorrhagic E. coli infections and disease. Drug Discovery Today 1: 73-79.
119. Vossenkämper A, Marchès O, Fairclough PD, Warnes G, Stagg A.J., Lindsay JO, Evans PC, Luong LA, Croft NM, Naik S., et al. 2010. Inhibition of NF-κB signaling in human dendritic cells by the enteropathogenic Escherichia coli effector protein NleE. J Immunol 185: 4118-4127.
120. Wales A.D., Woodward MJ, Pearson GR. 2005. Attachingeffacing bacteria in animals. J Comp Pathol 132: 1-26.
121. Wlodarska M., Willing B, Keeney KM, Menendez A, Bergstrom KS, Gill N, Russell SL, Vallance BA, Finlay BB. 2011. Antibiotic treatment alters the colonic mucus layer and predisposes the host to exacerbated Citrobacter rodentium-induced colitis. Infect Immun 79: 1536-1545.
122. Wong A.R.C., Pearson JS, Bright MD, Munera D, Robinson KS, Lee SF, Frankel G, Hartland EL. 2011. Enteropathogenic and enterohaemorrhagic Escherichia coli: Even more subversive elements. Mol Microbiol 80: 1420-1438.
123. Zhang Q., Li Q, Wang C, Li N, Li J. 2010a. Redistribution of tight junction proteins during EPEC infection in vivo. Inflammation 35: 23-32.
124. Zhang Q., Li Q, Wang C, Liu X, Li N, Li J. 2010b. Enteropathogenic Escherichia coli changes distribution of occludin and ZO-1 in tight junction membrane microdomains in vivo. Microb Pathogenesis 48: 28-34.
125. Zheng Y., Valdez PA, Danilenko DM, Hu Y, Sa SM, Gong Q, Abbas A.R., Modrusan Z, Ghilardi N, de Sauvage FJ, et al. 2008. Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. Nat Med 14: 282-289.
126. Zhu C., Feng S, Thate TE, Kaper JB, Boedeker EC. 2006. Towards a vaccine for attaching/effacing Escherichia coli: A LEE encoded regulator (ler) mutant of rabbit enteropathogenic Escherichia coli is attenuated, immunogenic, and protects rabbits from lethal challenge with the wild-type virulent strain. Vaccine 24: 3845-3855.